Selected research
Industry Research
Specific COX-2 Inhibitors Industry Research Report 2026
Market perspective
The global Specific COX-2 Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Specific COX-2 Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Specific COX-2 Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Specific COX-2 Inhibitors include Actavis, Eskayef Pharmaceuticals, Mylan Pharmaceutical, Neopharmed Gentili, Organon Pharma, Pfizer, Teva, Zentiva and Zydus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Specific COX-2 Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Specific COX-2 Inhibitors Market by Company
Actavis
Eskayef Pharmaceuticals
Mylan Pharmaceutical
Neopharmed Gentili
Organon Pharma
Pfizer
Teva
Zentiva
Zydus
Beijing Yabao Biological Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Jiangsu Chiatai Qingjiang Pharmaceutical
Qilu Pharmaceutical
Qingdao Baheal Medical
Shanxi Tongda Pharmaceutical
Sichuan Kelun Pharmaceutical
Specific COX-2 Inhibitors Segment by Type
Etoricoxib
Celecoxib
Imrecoxib
Other
Specific COX-2 Inhibitors Segment by Application
Osteoarthritis and Rheumatoid Arthritis
Relieve Acute Pain
Dysmenorrhea
Other
Specific COX-2 Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Specific COX-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Specific COX-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Specific COX-2 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Specific COX-2 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Specific COX-2 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Specific COX-2 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Specific COX-2 Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Specific COX-2 Inhibitors Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Specific COX-2 Inhibitors Revenue of Manufacturers (2021-2026)
Table 9. Global Specific COX-2 Inhibitors Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Specific COX-2 Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Specific COX-2 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Specific COX-2 Inhibitors, Product Type & Application
Table 14. Global Specific COX-2 Inhibitors Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Specific COX-2 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Actavis Company Information
Table 19. Actavis Business Overview
Table 20. Actavis Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Actavis Specific COX-2 Inhibitors Product Portfolio
Table 22. Actavis Recent Developments
Table 23. Eskayef Pharmaceuticals Company Information
Table 24. Eskayef Pharmaceuticals Business Overview
Table 25. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
Table 27. Eskayef Pharmaceuticals Recent Developments
Table 28. Mylan Pharmaceutical Company Information
Table 29. Mylan Pharmaceutical Business Overview
Table 30. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
Table 32. Mylan Pharmaceutical Recent Developments
Table 33. Neopharmed Gentili Company Information
Table 34. Neopharmed Gentili Business Overview
Table 35. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
Table 37. Neopharmed Gentili Recent Developments
Table 38. Organon Pharma Company Information
Table 39. Organon Pharma Business Overview
Table 40. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Organon Pharma Specific COX-2 Inhibitors Product Portfolio
Table 42. Organon Pharma Recent Developments
Table 43. Pfizer Company Information
Table 44. Pfizer Business Overview
Table 45. Pfizer Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Pfizer Specific COX-2 Inhibitors Product Portfolio
Table 47. Pfizer Recent Developments
Table 48. Teva Company Information
Table 49. Teva Business Overview
Table 50. Teva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Teva Specific COX-2 Inhibitors Product Portfolio
Table 52. Teva Recent Developments
Table 53. Zentiva Company Information
Table 54. Zentiva Business Overview
Table 55. Zentiva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Zentiva Specific COX-2 Inhibitors Product Portfolio
Table 57. Zentiva Recent Developments
Table 58. Zydus Company Information
Table 59. Zydus Business Overview
Table 60. Zydus Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Zydus Specific COX-2 Inhibitors Product Portfolio
Table 62. Zydus Recent Developments
Table 63. Beijing Yabao Biological Pharmaceutical Company Information
Table 64. Beijing Yabao Biological Pharmaceutical Business Overview
Table 65. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
Table 67. Beijing Yabao Biological Pharmaceutical Recent Developments
Table 68. Jiangsu Hengrui Pharmaceuticals Company Information
Table 69. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 70. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
Table 72. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 73. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
Table 74. Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
Table 75. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
Table 77. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
Table 78. Qilu Pharmaceutical Company Information
Table 79. Qilu Pharmaceutical Business Overview
Table 80. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
Table 82. Qilu Pharmaceutical Recent Developments
Table 83. Qingdao Baheal Medical Company Information
Table 84. Qingdao Baheal Medical Business Overview
Table 85. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
Table 87. Qingdao Baheal Medical Recent Developments
Table 88. Shanxi Tongda Pharmaceutical Company Information
Table 89. Shanxi Tongda Pharmaceutical Business Overview
Table 90. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
Table 92. Shanxi Tongda Pharmaceutical Recent Developments
Table 93. Sichuan Kelun Pharmaceutical Company Information
Table 94. Sichuan Kelun Pharmaceutical Business Overview
Table 95. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
Table 97. Sichuan Kelun Pharmaceutical Recent Developments
Table 98. Global Specific COX-2 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 99. Global Specific COX-2 Inhibitors Sales by Region (2021-2026) & (K Units)
Table 100. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021-2026)
Table 101. Global Specific COX-2 Inhibitors Sales by Region (2027-2032) & (K Units)
Table 102. Global Specific COX-2 Inhibitors Sales Market Share by Region (2027-2032)
Table 103. Global Specific COX-2 Inhibitors Revenue by Region (2021-2026) & (US$ Million)
Table 104. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021-2026)
Table 105. Global Specific COX-2 Inhibitors Revenue by Region (2027-2032) & (US$ Million)
Table 106. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2027-2032)
Table 107. North America Specific COX-2 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. North America Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 109. North America Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units)
Table 110. North America Specific COX-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 111. North America Specific COX-2 Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 112. Europe Specific COX-2 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. Europe Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 114. Europe Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units)
Table 115. Europe Specific COX-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 116. Europe Specific COX-2 Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 117. Asia Pacific Specific COX-2 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 118. Asia Pacific Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 119. Asia Pacific Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units)
Table 120. Asia Pacific Specific COX-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 121. Asia Pacific Specific COX-2 Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 122. South America Specific COX-2 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 123. South America Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 124. South America Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units)
Table 125. South America Specific COX-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 126. South America Specific COX-2 Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 127. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 128. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units)
Table 129. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units)
Table 130. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 131. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 132. Global Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units)
Table 133. Global Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units)
Table 134. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2026)
Table 135. Global Specific COX-2 Inhibitors Sales Market Share by Type (2027-2032)
Table 136. Global Specific COX-2 Inhibitors Revenue by Type (2021-2026) & (US$ Million)
Table 137. Global Specific COX-2 Inhibitors Revenue by Type (2027-2032) & (US$ Million)
Table 138. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2026)
Table 139. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2027-2032)
Table 140. Global Specific COX-2 Inhibitors Price by Type (2021-2026) & (US$/Unit)
Table 141. Global Specific COX-2 Inhibitors Price by Type (2027-2032) & (US$/Unit)
Table 142. Global Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units)
Table 143. Global Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units)
Table 144. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2026)
Table 145. Global Specific COX-2 Inhibitors Sales Market Share by Application (2027-2032)
Table 146. Global Specific COX-2 Inhibitors Revenue by Application (2021-2026) & (US$ Million)
Table 147. Global Specific COX-2 Inhibitors Revenue by Application (2027-2032) & (US$ Million)
Table 148. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2026)
Table 149. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2027-2032)
Table 150. Global Specific COX-2 Inhibitors Price by Application (2021-2026) & (US$/Unit)
Table 151. Global Specific COX-2 Inhibitors Price by Application (2027-2032) & (US$/Unit)
Table 152. Key Raw Materials
Table 153. Raw Materials Key Suppliers
Table 154. Specific COX-2 Inhibitors Distributors List
Table 155. Specific COX-2 Inhibitors Customers List
Table 156. Specific COX-2 Inhibitors Industry Trends
Table 157. Specific COX-2 Inhibitors Industry Drivers
Table 158. Specific COX-2 Inhibitors Industry Restraints
Table 159. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Specific COX-2 Inhibitors Product Image
Figure 5. Global Specific COX-2 Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Specific COX-2 Inhibitors Market Size (2021-2032) & (US$ Million)
Figure 7. Global Specific COX-2 Inhibitors Sales (2021-2032) & (K Units)
Figure 8. Global Specific COX-2 Inhibitors Average Price (US$/Unit) & (2021-2032)
Figure 9. Etoricoxib Product Image
Figure 10. Celecoxib Product Image
Figure 11. Imrecoxib Product Image
Figure 12. Other Product Image
Figure 13. Osteoarthritis and Rheumatoid Arthritis Product Image
Figure 14. Relieve Acute Pain Product Image
Figure 15. Dysmenorrhea Product Image
Figure 16. Other Product Image
Figure 17. Global Specific COX-2 Inhibitors Revenue Share by Manufacturers in 2025
Figure 18. Global Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 Specific COX-2 Inhibitors Players Market Share by Revenue in 2025
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. Global Specific COX-2 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 22. Global Specific COX-2 Inhibitors Sales by Region in 2025
Figure 23. Global Specific COX-2 Inhibitors Revenue by Region in 2025
Figure 24. North America Specific COX-2 Inhibitors Market Size by Country in 2025
Figure 25. North America Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032)
Figure 26. North America Specific COX-2 Inhibitors Revenue Market Share by Country (2021-2032)
Figure 27. United States Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Canada Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Mexico Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Europe Specific COX-2 Inhibitors Market Size by Country in 2025
Figure 31. Europe Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032)
Figure 32. Europe Specific COX-2 Inhibitors Revenue Market Share by Country (2021-2032)
Figure 33. Germany Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. France Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. U.K. Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Italy Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Russia Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Spain Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Netherlands Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Switzerland Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Sweden Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Poland Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Asia Pacific Specific COX-2 Inhibitors Market Size by Country in 2025
Figure 44. Asia Pacific Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032)
Figure 45. Asia Pacific Specific COX-2 Inhibitors Revenue Market Share by Country (2021-2032)
Figure 46. China Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. Japan Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. South Korea Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. India Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Australia Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Taiwan Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Southeast Asia Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Southeast Asia Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. South America Specific COX-2 Inhibitors Market Size by Country in 2025
Figure 55. South America Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032)
Figure 56. South America Specific COX-2 Inhibitors Revenue Market Share by Country (2021-2032)
Figure 57. Brazil Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Argentina Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Chile Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Colombia Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 61. Middle East and Africa Specific COX-2 Inhibitors Market Size by Country in 2025
Figure 62. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share by Country (2021-2032)
Figure 63. Middle East and Africa Specific COX-2 Inhibitors Revenue Market Share by Country (2021-2032)
Figure 64. Egypt Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. South Africa Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. Israel Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. Türkiye Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 68. GCC Countries Specific COX-2 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 69. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2032)
Figure 70. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2032)
Figure 71. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2021-2032)
Figure 72. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2032)
Figure 73. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2032)
Figure 74. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2021-2032)
Figure 75. Specific COX-2 Inhibitors Value Chain
Figure 76. Specific COX-2 Inhibitors Production Mode & Process
Figure 77. Direct Comparison with Distribution Share
Figure 78. Distributors Profiles
Figure 79. Specific COX-2 Inhibitors Industry Opportunities and Challenges
Scope & coverage.
Types
- Etoricoxib
- Celecoxib
- Imrecoxib
- Other
Applications
- Osteoarthritis and Rheumatoid Arthritis
- Relieve Acute Pain
- Dysmenorrhea
- Other
Companies covered
- Actavis
- Eskayef Pharmaceuticals
- Mylan Pharmaceutical
- Neopharmed Gentili
- Organon Pharma
- Pfizer
- Teva
- Zentiva
- Zydus
- Beijing Yabao Biological Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Jiangsu Chiatai Qingjiang Pharmaceutical
- Qilu Pharmaceutical
- Qingdao Baheal Medical
- Shanxi Tongda Pharmaceutical
- Sichuan Kelun Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Specific COX-2 Inhibitors Market Size (2021-2032)
- 2.2.2 Global Specific COX-2 Inhibitors Sales (2021-2032)
- 2.2.3 Global Specific COX-2 Inhibitors Market Average Price (2021-2032)
- 2.3 Specific COX-2 Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Etoricoxib
- 2.3.3 Celecoxib
- 2.3.4 Imrecoxib
- 2.3.5 Other
- 2.4 Specific COX-2 Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Osteoarthritis and Rheumatoid Arthritis
- 2.4.3 Relieve Acute Pain
- 2.4.4 Dysmenorrhea
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Specific COX-2 Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Specific COX-2 Inhibitors Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Specific COX-2 Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global Specific COX-2 Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global Specific COX-2 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Specific COX-2 Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Specific COX-2 Inhibitors, Established Date
- 3.9 Global Specific COX-2 Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Actavis
- 4.1.1 Actavis Company Information
- 4.1.2 Actavis Business Overview
- 4.1.3 Actavis Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Actavis Specific COX-2 Inhibitors Product Portfolio
- 4.1.5 Actavis Recent Developments
- 4.2 Eskayef Pharmaceuticals
- 4.2.1 Eskayef Pharmaceuticals Company Information
- 4.2.2 Eskayef Pharmaceuticals Business Overview
- 4.2.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
- 4.2.5 Eskayef Pharmaceuticals Recent Developments
- 4.3 Mylan Pharmaceutical
- 4.3.1 Mylan Pharmaceutical Company Information
- 4.3.2 Mylan Pharmaceutical Business Overview
- 4.3.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
- 4.3.5 Mylan Pharmaceutical Recent Developments
- 4.4 Neopharmed Gentili
- 4.4.1 Neopharmed Gentili Company Information
- 4.4.2 Neopharmed Gentili Business Overview
- 4.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
- 4.4.5 Neopharmed Gentili Recent Developments
- 4.5 Organon Pharma
- 4.5.1 Organon Pharma Company Information
- 4.5.2 Organon Pharma Business Overview
- 4.5.3 Organon Pharma Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
- 4.5.5 Organon Pharma Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Teva
- 4.7.1 Teva Company Information
- 4.7.2 Teva Business Overview
- 4.7.3 Teva Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
- 4.7.5 Teva Recent Developments
- 4.8 Zentiva
- 4.8.1 Zentiva Company Information
- 4.8.2 Zentiva Business Overview
- 4.8.3 Zentiva Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
- 4.8.5 Zentiva Recent Developments
- 4.9 Zydus
- 4.9.1 Zydus Company Information
- 4.9.2 Zydus Business Overview
- 4.9.3 Zydus Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Zydus Specific COX-2 Inhibitors Product Portfolio
- 4.9.5 Zydus Recent Developments
- 4.10 Beijing Yabao Biological Pharmaceutical
- 4.10.1 Beijing Yabao Biological Pharmaceutical Company Information
- 4.10.2 Beijing Yabao Biological Pharmaceutical Business Overview
- 4.10.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
- 4.10.5 Beijing Yabao Biological Pharmaceutical Recent Developments
- 4.11 Jiangsu Hengrui Pharmaceuticals
- 4.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.11.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
- 4.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.12 Jiangsu Chiatai Qingjiang Pharmaceutical
- 4.12.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
- 4.12.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
- 4.12.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
- 4.12.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
- 4.13 Qilu Pharmaceutical
- 4.13.1 Qilu Pharmaceutical Company Information
- 4.13.2 Qilu Pharmaceutical Business Overview
- 4.13.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
- 4.13.5 Qilu Pharmaceutical Recent Developments
- 4.14 Qingdao Baheal Medical
- 4.14.1 Qingdao Baheal Medical Company Information
- 4.14.2 Qingdao Baheal Medical Business Overview
- 4.14.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
- 4.14.5 Qingdao Baheal Medical Recent Developments
- 4.15 Shanxi Tongda Pharmaceutical
- 4.15.1 Shanxi Tongda Pharmaceutical Company Information
- 4.15.2 Shanxi Tongda Pharmaceutical Business Overview
- 4.15.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
- 4.15.5 Shanxi Tongda Pharmaceutical Recent Developments
- 4.16 Sichuan Kelun Pharmaceutical
- 4.16.1 Sichuan Kelun Pharmaceutical Company Information
- 4.16.2 Sichuan Kelun Pharmaceutical Business Overview
- 4.16.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
- 4.16.5 Sichuan Kelun Pharmaceutical Recent Developments
5 Global Specific COX-2 Inhibitors Market Scenario by Region
- 5.1 Global Specific COX-2 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Specific COX-2 Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global Specific COX-2 Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global Specific COX-2 Inhibitors Sales by Region: 2027-2032
- 5.3 Global Specific COX-2 Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global Specific COX-2 Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global Specific COX-2 Inhibitors Revenue by Region: 2027-2032
- 5.4 North America Specific COX-2 Inhibitors Market Facts & Figures by Country
- 5.4.1 North America Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Specific COX-2 Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America Specific COX-2 Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Specific COX-2 Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Specific COX-2 Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe Specific COX-2 Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Specific COX-2 Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Specific COX-2 Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Specific COX-2 Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Specific COX-2 Inhibitors Market Facts & Figures by Country
- 5.7.1 South America Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Specific COX-2 Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America Specific COX-2 Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Specific COX-2 Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Specific COX-2 Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global Specific COX-2 Inhibitors Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Specific COX-2 Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global Specific COX-2 Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global Specific COX-2 Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global Specific COX-2 Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Specific COX-2 Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global Specific COX-2 Inhibitors Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Specific COX-2 Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global Specific COX-2 Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global Specific COX-2 Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global Specific COX-2 Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Specific COX-2 Inhibitors Value Chain Analysis
- 8.1.1 Specific COX-2 Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Specific COX-2 Inhibitors Production Mode & Process
- 8.2 Specific COX-2 Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Specific COX-2 Inhibitors Distributors
- 8.2.3 Specific COX-2 Inhibitors Customers
9 Global Specific COX-2 Inhibitors Analyzing Market Dynamics
- 9.1 Specific COX-2 Inhibitors Industry Trends
- 9.2 Specific COX-2 Inhibitors Industry Drivers
- 9.3 Specific COX-2 Inhibitors Industry Opportunities and Challenges
- 9.4 Specific COX-2 Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst